Kenya is taking a major step in HIV prevention by administering lenacapavir, a long-acting injectable drug that provides six months of preventive protection from HIV with a single injection. This initiative allows Kenya to become one of the pioneering countries to adopt this breakthrough therapy, which has been recognized by Science magazine as the 'Breakthrough of the Year' in 2024. The injections, which are administered subcutaneously, will be offered free of charge at select public health facilities located within priority counties.

The rollout of lenacapavir is particularly significant as it enhances access to HIV prevention methods for various populations, including pregnant and breastfeeding mothers, who can use the drug safely. The Kenyan health authorities have ensured that systems are in place to monitor and manage any potential side effects of the treatment, raising confidence among patients regarding the new therapy. This move is seen as vital in addressing the growing need for effective HIV preventive strategies amid the backdrop of declining global funding for AIDS initiatives.

This initiative arrives at a crucial time as World AIDS Day approaches, a period designated for raising awareness and highlighting significant innovations and challenges in the ongoing battle against HIV/AIDS. With the introduction of lenacapavir, Kenya hopes to set a precedent that could inspire other countries to adopt similar measures, ultimately contributing to the global fight against the HIV epidemic and improving health outcomes for those at risk.